Pronociceptive and Antinociceptive Effects of Buprenorphine in the Spinal Cord Dorsal Horn Cover a Dose Range of Four Orders of Magnitude
Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nocicepti...
Saved in:
Published in | The Journal of neuroscience Vol. 35; no. 26; pp. 9580 - 9594 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Society for Neuroscience
01.07.2015
|
Subjects | |
Online Access | Get full text |
ISSN | 0270-6474 1529-2401 1529-2401 |
DOI | 10.1523/JNEUROSCI.0731-14.2015 |
Cover
Abstract | Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn in vivo. At an analgesically active dose of 1500 μg·kg(-1), buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively μ1-opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective μ1-opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 μg·kg(-1)), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive μ-opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT2Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct μ-opioid receptor subtypes located at different levels of the neuraxis. |
---|---|
AbstractList | Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn
in vivo
. At an analgesically active dose of 1500 μg·kg
−1
, buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively μ
1
-opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective μ
1
-opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 μg·kg
−1
), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive μ-opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT
2
Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct μ-opioid receptor subtypes located at different levels of the neuraxis. Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn in vivo. At an analgesically active dose of 1500 μg·kg(-1), buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively μ1-opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective μ1-opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 μg·kg(-1)), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive μ-opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT2Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct μ-opioid receptor subtypes located at different levels of the neuraxis.Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn in vivo. At an analgesically active dose of 1500 μg·kg(-1), buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively μ1-opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective μ1-opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 μg·kg(-1)), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive μ-opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT2Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct μ-opioid receptor subtypes located at different levels of the neuraxis. Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn in vivo. At an analgesically active dose of 1500 μg·kg(-1), buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively μ1-opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective μ1-opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 μg·kg(-1)), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive μ-opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT2Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct μ-opioid receptor subtypes located at different levels of the neuraxis. Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, despite its wide clinical use, little is known about the synaptic effects of buprenorphine in nociceptive pathways. Here, we demonstrate dose-dependent, bimodal effects of buprenorphine on transmission at C-fiber synapses in rat spinal cord dorsal horn in vivo. At an analgesically active dose of 1500 mu g times kg super(-1), buprenorphine reduced the strength of spinal C-fiber synapses. This depression required activation of spinal opioid receptors, putatively mu sub(1)-opioid receptors, as indicated by its sensitivity to spinal naloxone and to the selective mu sub(1)-opioid receptor antagonist naloxonazine. In contrast, a 15,000-fold lower dose of buprenorphine (0.1 mu g times kg super(-1)), which caused thermal and mechanical hyperalgesia in behaving animals, induced an enhancement of transmission at spinal C-fiber synapses. The ultra-low-dose buprenorphine-induced synaptic facilitation was mediated by supraspinal naloxonazine-insensitive, but CTOP-sensitive mu -opioid receptors, descending serotonergic pathways, and activation of spinal glial cells. Selective inhibition of spinal 5-hydroxytryptamine-2 receptors (5-HT sub(2)Rs), putatively located on spinal astrocytes, abolished both the induction of synaptic facilitation and the hyperalgesia elicited by ultra-low-dose buprenorphine. Our study revealed that buprenorphine mediates its modulatory effects on transmission at spinal C-fiber synapses by dose dependently acting on distinct mu -opioid receptor subtypes located at different levels of the neuraxis. |
Author | Drdla-Schutting, R. Gerhold, K. J. Honsek, S. D. Sandkuhler, J. Forsthuber, L. |
Author_xml | – sequence: 1 givenname: K. J. surname: Gerhold fullname: Gerhold, K. J. – sequence: 2 givenname: R. surname: Drdla-Schutting fullname: Drdla-Schutting, R. – sequence: 3 givenname: S. D. surname: Honsek fullname: Honsek, S. D. – sequence: 4 givenname: L. surname: Forsthuber fullname: Forsthuber, L. – sequence: 5 givenname: J. surname: Sandkuhler fullname: Sandkuhler, J. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26134641$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUl1vEzEQtFARTQt_ofIjLxfs81dPQkglpLSoENTSZ8ux9xKji33Yd5H4Cf3XdWiJCi998mp2ZnZXniN0EGIAhE4omVJRs3dfvs1vrxc3s8spUYxWlE9rQsULNCndpqo5oQdoQmpFKskVP0RHOf8khChC1St0WEvKuOR0gu6-pxii9Rb6wW8Bm-DwWRj8U2zetmCHjGOLP459ghBTv_YBsA94WAO-6X0wHZ7F5PCnmHKpL2IKBdhCwqZgGfC1CSvYWZzHMeFFcpD-OH41q-CH0cFr9LI1XYY3j-8xuj2f_5hdVFeLz5ezs6vKcq6GCrhoFBXKqdNaEOesbJeULYERx5eS0VJJUQtqGRDBnDCGnBbAgbUOagnsGH148O3H5QachTAk0-k--Y1Jv3U0Xv_bCX6tV3GruShzCSkGbx8NUvw1Qh70xmcLXWcCxDFrqmolm4bV8nmqbJiiDVe0UE-errXf5-9XFYJ8INgUc07Q7imU6F0m9D4TepcJTbneZaII3_8ntH4wg4-783z3nPweXCO_tg |
CitedBy_id | crossref_primary_10_1038_s41386_021_01200_5 crossref_primary_10_1038_s41598_021_88030_z crossref_primary_10_1186_s44158_024_00201_2 crossref_primary_10_1038_s41598_017_11120_4 crossref_primary_10_1007_s40122_019_00143_6 crossref_primary_10_1038_s41598_017_02509_2 crossref_primary_10_1002_ejp_1328 crossref_primary_10_1016_j_brainres_2021_147445 crossref_primary_10_1016_j_pnpbp_2019_02_010 crossref_primary_10_3389_fimmu_2020_00300 crossref_primary_10_1016_j_neuroscience_2016_06_029 crossref_primary_10_1152_jn_00680_2016 crossref_primary_10_1007_s40265_018_0953_z crossref_primary_10_1113_JP283021 crossref_primary_10_1016_j_peptides_2016_12_004 crossref_primary_10_1523_JNEUROSCI_1182_22_2022 crossref_primary_10_1002_ame2_12157 |
ContentType | Journal Article |
Copyright | Copyright © 2015 Gerhold, Drdla-Schutting et al. Copyright © 2015 Gerhold, Drdla-Schutting et al. 2015 |
Copyright_xml | – notice: Copyright © 2015 Gerhold, Drdla-Schutting et al. – notice: Copyright © 2015 Gerhold, Drdla-Schutting et al. 2015 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7TK 7U7 C1K 5PM |
DOI | 10.1523/JNEUROSCI.0731-14.2015 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Neurosciences Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Toxicology Abstracts Neurosciences Abstracts Environmental Sciences and Pollution Management |
DatabaseTitleList | MEDLINE - Academic MEDLINE Toxicology Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 1529-2401 |
EndPage | 9594 |
ExternalDocumentID | PMC4571500 26134641 10_1523_JNEUROSCI_0731_14_2015 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -DZ -~X .55 18M 2WC 34G 39C 53G 5GY 5RE 5VS AAFWJ AAJMC AAYXX ABBAR ABIVO ACGUR ACNCT ADBBV ADCOW ADHGD AENEX AETEA AFCFT AFOSN AFSQR AHWXS ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P GX1 H13 HYE H~9 KQ8 L7B OK1 P0W P2P QZG R.V RHI RPM TFN TR2 W8F WH7 WOQ X7M XJT YBU YHG YKV YNH YSK CGR CUY CVF ECM EIF NPM 7X8 7TK 7U7 C1K 5PM |
ID | FETCH-LOGICAL-c447t-e4597157d78250ddc6fb13be30d4b631be365251c3e053d5aa08652deccde26e3 |
ISSN | 0270-6474 1529-2401 |
IngestDate | Thu Aug 21 14:04:55 EDT 2025 Fri Sep 05 06:21:33 EDT 2025 Fri Sep 05 07:34:27 EDT 2025 Thu Apr 03 07:00:55 EDT 2025 Thu Apr 24 23:12:29 EDT 2025 Tue Jul 01 03:47:24 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 26 |
Keywords | descending facilitation pain buprenorphine spinal cord synapse opioid |
Language | English |
License | Copyright © 2015 Gerhold, Drdla-Schutting et al. This article is freely available online through the J Neurosci Author Open Choice option. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c447t-e4597157d78250ddc6fb13be30d4b631be365251c3e053d5aa08652deccde26e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 K.J.G. and R.D.-S. contributed equally to this work. Author contributions: K.J.G., R.D.-S., and J.S. designed research; K.J.G., R.D.-S., S.D.H., and L.F. performed research; K.J.G. and R.D.-S. analyzed data; K.J.G., R.D.-S., and J.S. wrote the paper. |
ORCID | 0000-0003-0645-986X 0000-0002-5209-485X |
OpenAccessLink | https://www.jneurosci.org/content/jneuro/35/26/9580.full.pdf |
PMID | 26134641 |
PQID | 1693719471 |
PQPubID | 23479 |
PageCount | 15 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4571500 proquest_miscellaneous_1727699326 proquest_miscellaneous_1693719471 pubmed_primary_26134641 crossref_primary_10_1523_JNEUROSCI_0731_14_2015 crossref_citationtrail_10_1523_JNEUROSCI_0731_14_2015 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-07-01 2015-Jul-01 20150701 |
PublicationDateYYYYMMDD | 2015-07-01 |
PublicationDate_xml | – month: 07 year: 2015 text: 2015-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of neuroscience |
PublicationTitleAlternate | J Neurosci |
PublicationYear | 2015 |
Publisher | Society for Neuroscience |
Publisher_xml | – name: Society for Neuroscience |
SSID | ssj0007017 |
Score | 2.2773461 |
Snippet | Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 9580 |
SubjectTerms | Analgesics, Opioid - pharmacology Animals Animals, Newborn Astrocytes - drug effects Buprenorphine - pharmacology Dose-Response Relationship, Drug Hyperalgesia - drug therapy In Vitro Techniques Male Naloxone - analogs & derivatives Naloxone - pharmacology Nerve Fibers, Unmyelinated - drug effects Nerve Fibers, Unmyelinated - metabolism Pain Measurement - drug effects Pain Threshold - drug effects Phosphopyruvate Hydratase - metabolism Rats Rats, Sprague-Dawley Signal Transduction - drug effects Spinal Cord - cytology Spinal Nerve Roots - cytology Synapses - drug effects Time Factors |
Title | Pronociceptive and Antinociceptive Effects of Buprenorphine in the Spinal Cord Dorsal Horn Cover a Dose Range of Four Orders of Magnitude |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26134641 https://www.proquest.com/docview/1693719471 https://www.proquest.com/docview/1727699326 https://pubmed.ncbi.nlm.nih.gov/PMC4571500 |
Volume | 35 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKeOEFAePScZGREC9Vsiaxk-axdCulwLh0k_YWxYmjVhrJlCZI8A_4d_wkzrEzN-mmwXiJUic-dXy-HJ8Tnwshr0Ivi1niCNxhHFkM-GCNXDGyYLFlgsV-OOIYjfzxyJ-dsPkpP-31fre8lupK2MnPK-NK_oer0AZ8xSjZG3DWEIUGOAf-whE4DMd_4vHnsshhcpVnyne9DzDGyg-ttsONv8abGvNXFjCxK50qBHXOxbkqizXBqMGDolyrUiIlRgLCbAxiaFvLwVeMQEASUxjV4BNm62x8Z9D3qE477kSbYDOl5rYSZhoMvZXlsqlW_d4ezG2jTZfpWWwtkmWtvLEV-83FGfp9K9m9sAcHpnkKg66WtdDQ-2C3P2M43Li8Xkg7NwA7lumSPbZspLGrtn-ctrjW2U0aWLpt4RtyXRSqWchDrssnX1okuEpWMT9CX8nF5J0NUs6xHPzApiNLu1m5t1ZL48OI1hNQigydCOmAKRUhnVvkthuANoduAl82-euDoaoBbR62iVkHOvtXj6erLl2ygbZdeVu60fE9crfhNh1rhN4nPZk_ILvjPK6Kbz_oa6rcjNX-zS751QUtBdDSLdDSBrS0yGgHtHSVUwAt1aClCFqqQUsRtFSBlsYUQUsVaJEEgpZq0OJPA9qH5GR6eDyZWU09ECthLKgsycD6dXiQglbLh2ma-JlwPCG9YcqE7zlw5nPQ1xMP652kPI7BXuduClIqla4vvUdkJy9y-YRQ13WGSSwCsNZc5o38MGHCk2AcDTORcZH1Cb-Y9ihpkuVjzZaz6Hq298m-6Xeu08X8tcfLC65GINlxuy7OZVGvI0yTFDghaI_X3APmhx-iDdYnjzUSzP-6oKkzn0HvoIMRcwNmlu9eyVdLlWGe8QDnYu_GT_OU3Nm83M_ITlXW8jlo7ZV4oV6EPy7O6ec |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pronociceptive+and+Antinociceptive+Effects+of+Buprenorphine+in+the+Spinal+Cord+Dorsal+Horn+Cover+a+Dose+Range+of+Four+Orders+of+Magnitude&rft.jtitle=The+Journal+of+neuroscience&rft.au=Gerhold%2C+K.+J.&rft.au=Drdla-Schutting%2C+R.&rft.au=Honsek%2C+S.+D.&rft.au=Forsthuber%2C+L.&rft.date=2015-07-01&rft.issn=0270-6474&rft.eissn=1529-2401&rft.volume=35&rft.issue=26&rft.spage=9580&rft.epage=9594&rft_id=info:doi/10.1523%2FJNEUROSCI.0731-14.2015&rft.externalDBID=n%2Fa&rft.externalDocID=10_1523_JNEUROSCI_0731_14_2015 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-6474&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-6474&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-6474&client=summon |